Literature DB >> 19506885

Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis.

Lia-Beng Tan1, Kow-Tong Chen, Yu-Chang Yuan, Pao-Chi Liao, How-Ran Guo.   

Abstract

OBJECTIVE: To determine the patterns of urinary proteins in bladder cancer subjects using pooled urine from 27 bladder cancer patients.
METHODS: The urine matrix was removed by acetonitrile precipitation followed by molecular weight cutoff. High performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) was used to analyze the urinary proteome. The candidate protein was validated by western blot.
RESULTS: A total of 146 urinary proteins were identified. The protein list was screened using bioinformatic tools, and 11 cancer-related urinary proteins were found to be potential tumor markers for bladder cancer. However, only PLK2 was identified with high confidence. This candidate protein was validated by western blot using urine samples from 14 normal subjects and 10 bladder cancer patients. Statistically significant correlations were detected between PLK2 expression and bladder transitional cell carcinoma (TCC) (P < 0.05). Urinary PLK2 had a sensitivity of 80% at a specificity of 64% for bladder TCC in the samples tested.
CONCLUSIONS: Our results demonstrate overexpression of PLK2 in bladder carcinomas, suggesting a possible role of PLK2 in the pathogenesis of bladder carcinomas. However, the small cohort, preliminary results, and lack of subgroup analysis (such as carcinoma in situ, high grade, and stage) in this study prevent us from drawing definitive conclusions about the diagnostic value of PLK2 in these patients. Further studies directed toward a multitude of possible carcinogenic mechanisms of PLK2 in bladder cancer are warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506885     DOI: 10.1007/s00345-009-0432-y

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  28 in total

1.  Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest.

Authors:  C S Spahr; M T Davis; M D McGinley; J H Robinson; E J Bures; J Beierle; J Mort; P L Courchesne; K Chen; R C Wahl; W Yu; R Luethy; S D Patterson
Journal:  Proteomics       Date:  2001-01       Impact factor: 3.984

2.  Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder.

Authors:  Celina Ang; Ann F Chambers; Alan B Tuck; Eric Winquist; Jonathan I Izawa
Journal:  BJU Int       Date:  2005-10       Impact factor: 5.588

Review 3.  Cell cycle kinases in cancer.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Curr Opin Genet Dev       Date:  2007-02       Impact factor: 5.578

4.  Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma.

Authors:  Beat M Künzli; Pascal O Berberat; Zhaowhen W Zhu; Marcus Martignoni; Jörg Kleeff; Adrien A Tempia-Caliera; Minoru Fukuda; Arthur Zimmermann; Helmut Friess; Markus W Büchler
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

5.  T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells.

Authors:  Yohei Mukoyama; Shuxia Zhou; Yoshiki Miyachi; Norihisa Matsuyoshi
Journal:  J Invest Dermatol       Date:  2005-04       Impact factor: 8.551

6.  Proteomic analysis for human urinary proteins associated with arsenic intoxication.

Authors:  Lia-Beng Tan; Kow-Tong Chen; Yu-Chang Tyan; Pao-Chi Liao; How-Ran Guo
Journal:  Proteomics Clin Appl       Date:  2008-07       Impact factor: 3.494

7.  Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein.

Authors:  Sun Young Yoon; Younghee Lee; Joo Heon Kim; An-Sik Chung; Joung Hyuck Joo; Chang-Nam Kim; Nam-Soon Kim; In Seong Choe; Jae Wha Kim
Journal:  Biochem Biophys Res Commun       Date:  2005-01-07       Impact factor: 3.575

8.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

9.  Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns.

Authors:  Hideaki Miyake; Isao Hara; Sadao Kamidono; Hiroshi Eto
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

10.  Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer.

Authors:  M F Sarosdy; R W deVere White; M S Soloway; J Sheinfeld; M A Hudson; P F Schellhammer; M V Jarowenko; G Adams; B A Blumenstein
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

View more
  12 in total

1.  Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer.

Authors:  Michela de Martino; Shahrokh F Shariat; Sebastian L Hofbauer; Ilaria Lucca; Christopher Taus; Helene G Wiener; Andrea Haitel; Martin Susani; Tobias Klatte
Journal:  World J Urol       Date:  2014-02-23       Impact factor: 4.226

Review 2.  Developing proteomic biomarkers for bladder cancer: towards clinical application.

Authors:  Maria Frantzi; Agnieszka Latosinska; Leif Flühe; Marie C Hupe; Elena Critselis; Mario W Kramer; Axel S Merseburger; Harald Mischak; Antonia Vlahou
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

Review 3.  Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Authors:  Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks
Journal:  Nat Rev Urol       Date:  2013-02-26       Impact factor: 14.432

4.  Plk2-mediated phosphorylation and translocalization of Nrf2 activates anti-inflammation through p53/Plk2/p21cip1 signaling in acute kidney injury.

Authors:  Da-Eun Kim; Hye Eun Byeon; Dae-Hoon Kim; Sang Geon Kim; Hyungshin Yim
Journal:  Cell Biol Toxicol       Date:  2022-07-16       Impact factor: 6.819

5.  Polo-like kinases mediate cell survival in mitochondrial dysfunction.

Authors:  Takumi Matsumoto; Ping-Yuan Wang; Wenzhe Ma; Ho Joong Sung; Satoaki Matoba; Paul M Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-11       Impact factor: 11.205

6.  Proteomics research on muscle-invasive bladder transitional cell carcinoma.

Authors:  Hai Tao Niu; Zhen Dong; Gang Jiang; Ting Xu; Yan Qun Liu; Yan Wei Cao; Jun Zhao; Xin Sheng Wang
Journal:  Cancer Cell Int       Date:  2011-06-07       Impact factor: 5.722

7.  PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.

Authors:  Zheng Bo Hu; Xiao Hong Liao; Zun Ying Xu; Xiao Yang; Chao Dong; An Min Jin; Hai Lu
Journal:  Cancer Med       Date:  2015-12-02       Impact factor: 4.452

Review 8.  Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions.

Authors:  Maria Frantzi; Antonia Vlahou
Journal:  Bladder Cancer       Date:  2017-01-27

9.  PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.

Authors:  Wenhu Li; Xianliao Zhang; Xinhua Xi; Yufa Li; Hong Quan; Shifeng Liu; Liqi Wu; Penghuan Wu; Wenxing Lan; Yongjun Shao; Haomiao Li; Kebing Chen; Zhengbo Hu
Journal:  Cancer Med       Date:  2020-04-29       Impact factor: 4.452

10.  Polo-like kinase 2 acting as a promoter in human tumor cells with an abundance of TAp73.

Authors:  ZhengBo Hu; ZunYing Xu; XiaoHong Liao; Xiao Yang; Cao Dong; KuaDi Luk; AnMin Jin; Hai Lu
Journal:  Onco Targets Ther       Date:  2015-11-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.